Randomized Study of Obicetrapib in Combination With Ezetimibe

Summary

This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.

Timeline

Start

2021-02-23

Primary completion

2021-05-07

Completion

2021-06-30

Publications

• Pirillo A, Catapano AL. The two faces of cholesteryl ester transfer protein inhibitors. Curr Opin Lipidol. 2025 Dec 1;36(6):318-325. doi: 10.1097/MOL.0000000000001017. Epub 2025 Oct 13.

Drugs

Indications